Fluid management in acute kidney injury

Acute kidney injury (AKI) and fluids are closely linked through oliguria, which is a marker of the former and a trigger for administration of the latter. Recent progress in this field has challenged the physiological and clinical rational of using oliguria as a trigger for the administration of fluid and brought attention to the delicate balance between benefits and harms of different aspects of fluid management in critically ill patients, in particular those with AKI. This narrative review addresses various aspects of fluid management in AKI outlining physiological aspects, the effects of crystalloids and colloids on kidney function and the effect of various resuscitation and de-resuscitation strategies on the course and outcome of AKI.     

Ventilatory management in acute lung injury

Practical theoretic aspects of the adult respiratory distress syndrome and its application to the patient are presented. Rational utilization of mechanical ventilation and positive end-expiratory pressure in the management of hypoxemia is discussed in detail.     

Fluid management and diuretic therapy in acute renal failure

Acute renal failure (ARF) is a common problem in critical care; therefore, nurses should consider it to be a potential issue for all of their patients. Fluid management and diuretic therapy are important in these patients. The aim of this study is to review the use of these interventions in patients in acute renal failure. Initially, the paper will review renal physiology and discuss some of the causes of acute renal failure. This will be followed by a critical examination of the evidence surrounding the use of crystalloids and colloids for fluid resuscitation, as well as the role of diuretics in patients with acute renal failure. The paper concludes by identifying approaches for developing future practice in this area.     

Fluid balance in critically ill children with acute lung injury*

OBJECTIVES:: In the Fluid and Catheter Treatment Trial (NCT00281268), adults with acute lung injury randomized to a conservative vs. liberal fluid management protocol had increased days alive and free of mechanical ventilator support (ventilator-free days). Recruiting sufficient children with acute lung injury into a pediatric trial is challenging. A Bayesian statistical approach relies on the adult trial for the a priori effect estimate, requiring fewer patients. Preparing for a Bayesian pediatric trial mirroring the Fluid and Catheter Treatment Trial, we aimed to: 1) identify an inverse association between fluid balance and ventilator-free days; and 2) determine if fluid balance over time is more similar to adults in the Fluid and Catheter Treatment Trial liberal or conservative arms. DESIGN:: Multicentered retrospective cohort study. SETTING:: Five pediatric intensive care units. PATIENTS:: Mechanically ventilated children (age ≥1 month to <18 yrs) with acute lung injury admitted in 2007-2010. INTERVENTIONS:: None. MEASUREMENTS AND MAIN RESULTS:: Fluid intake, output, and net fluid balance were collected on days 1-7 in 168 children with acute lung injury (median age 3 yrs, median PaO2/FIO2 138) and weight-adjusted (mL/kg). Using multivariable linear regression to adjust for age, gender, race, admission day illness severity, PaO2/FIO2, and vasopressor use, increasing cumulative fluid balance (mL/kg) on day 3 was associated with fewer ventilator-free days (p = .02). Adjusted for weight, daily fluid balance on days 1-3 and cumulative fluid balance on days 1-7 were higher in these children compared to adults in the Fluid and Catheter Treatment Trial conservative arm (p < .001, each day) and was similar to adults in the liberal arm. CONCLUSIONS:: Increasing fluid balance on day 3 in children with acute lung injury at these centers is independently associated with fewer ventilator-free days. Our findings and the similarity of fluid balance patterns in our cohort to adults in the Fluid and Catheter Treatment Trial liberal arm demonstrate the need to determine whether a conservative fluid management strategy improves clinical outcomes in children with acute lung injury and support a Bayesian trial mirroring the Fluid and Catheter Treatment Trial.     

Evidence-based management of acute lung injury and acute respiratory distress syndrome

This report explores the efficacy of existing therapies for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), primarily in terms of clinically important outcomes such as the duration of mechanical ventilation and hospital mortality. Of the 15 therapies reviewed, the strongest evidence suggests that ALI/ARDS should be managed with a low-tidal-volume, pressure-limited approach, with either low or moderately high positive end-expiratory pressure. To date there have been few large, sufficiently powered, randomized controlled clinical trials of ALI/ARDS therapies that addressed patient outcomes. However, there is relatively strong evidence to support conservative fluid management and high-fat, anti-oxidant nutritional formulations. Although most pharmacologic ALI/ARDS therapies have been ineffective, high-dose methylprednisolone is indicated in the subgroups of ALI/ARDS patients who have pneumonia or are at risk of ARDS due to fat embolization.     

Fluid management in hospitalized patients

Intravenous fluid administration is critical to the care of hospitalized patients. Despite the lack of a clear consensus on fluid administration, one may use the principles in this article to develop an organized framework for patient care. The authors have stated that they do not have a significant financial interest or other relationship with any product manufacturer or provider of services discussed in this article. The authors also do not discuss the use of off-label products, which includes unlabeled, unapproved, or investigative products or devices.     

Fluid management: the pharmacoeconomic dimension

Cost is a key concern in fluid management. Relatively few data are available that address the comparative total costs of care between different fluid management regimens in particular clinical indications. Relevant costs of fluid-associated morbidity and mortality, including those incurred after intensive care unit or hospital discharge, also need to be considered in evaluating the cost-benefit ratios of administered fluids. Rigorously designed pharmacoeconomic studies are needed to delineate the costs and benefits of various approaches to fluid management.     

Fluid management strategies in heart failure

In patients with chronic heart failure, fluid retention (or hypervolemia) is often the stimulus for acute decompensated heart failure that requires hospitalization. The pathophysiology of fluid retention is complex and involves both hemodynamic and clinical congestion. Signs and symptoms of both hemodynamic and clinical congestion should be assessed serially during hospitalization. Core heart failure drug and cardiac device therapies should be provided, and ultrafiltration may be warranted. Critical care, intermediate care, and telemetry nurses have roles in both assessment and management of patients hospitalized with acute decompensated heart failure and fluid retention. Nurse administrators and managers have heightened their attention to fluid retention because the Medicare performance measure known as the risk-standardized 30-day all-cause readmission rate after heart failure hospitalization can be attenuated by fluid management strategies initiated by nurses during a patient's hospitalization.     

原位肝移植术中液体的管理

目的 分析影响原位肝移植术中补液的因素。方法 96例肝移植患者根据其术前肝功能不同分为晚期肝硬化组（ChildC级。50例）和非晚期肝硬化组（ChildA级或B级，46例）；非晚期肝硬化组根据术中出血量又分为A亚组（出血〈2000m1）和B亚组（出血≥2000m1）。监测手术前后血浆白蛋白与凝血功能变化，记录术中出血及输入血液制品情况。结果 晚期肝硬化组术前血浆凝血酶原时间（PT）和活化部分凝血活酶时间（APTT）均显著长于非晚期肝硬化组（P均〈O．05）；血小板和纤维蛋白原均显著低于非晚期肝硬化组（P均〈0．05）。术毕两组各指标差异均无显著性（P均〉0．05）。非晚期肝硬化组中A亚组术中输入各种血液制品量显著低于晚期肝硬化组（P均〈0．05）；B亚组术中输入各种血液制品量与晚期肝硬化组比较差异均无显著性（P均〉O．05）。结论 肝移植术中，肝硬化晚期或出血量大的患者需要补充更多的血液制品。     

Biomarkers in acute lung injury: insights into the pathogenesis of acute lung injury

Studies of potential biomarkers of acute lung injury (ALI) have provided information relating to the pathophysiology of the mechanisms of lung injury and repair. The utility of biomarkers remains solely among research tools to investigate lung injury and repair mechanisms. Because of lack of sensitivity and specificity, they cannot be used in decision making in patients with ALI or acute respiratory distress syndrome. The authors reviewed known biomarkers in context of their major biologic activity. The continued interest in identifying and studying biomarkers is relevant, as it provides information regarding the mechanisms involved in lung injury and repair and how this may be helpful in identifying and designing future therapeutic targets and strategies and possibly identifying a sensitive and specific biomarker.     

脓毒性休克早期液体复苏的临床研究

目的:探讨早期液体复苏容量对脓毒性休克的治疗意义。方法:定义正平衡即液体入量大于液体出量,负平衡即液体入量小于液体出量。回顾性分析80例脓毒性休克患者入院后24h和入院后72h液体复苏正平衡组及负平衡组的资料,分析两组间患者的预后。结果:入院后24h内负平衡组,负平衡液体量-218±21.4ml,死亡率显著低于正平衡组,正平衡液体量3206±57.9ml(P<0.01)。入院后72h内负平衡组,负平衡液体量-278±25.9ml,死亡率显著低于正平衡组,正平衡液体量5265±98.7ml(P<0.01)。结论:脓毒性休克患者早期液体复苏容量负平衡可以降低病死率。     

Fluid management in children with diabetic ketoacidosis

QuestionPrevious research has indicated that rapid rehydration in children with type 1 diabetes who present with diabetic ketoacidosis could result in cerebral edema. I have been treating patients with diabetic ketoacidosis with gradual fluid replacement. With the risk of cerebral injury in these patients, should I continue management with slow fluid rehydration?AnswerRecent research has shown that neither fluid infusion rate nor sodium chloride concentration increases risk of cerebral injury. However, it is possible for subtle brain injury to occur during treatment, regardless of the fluid administration strategy. The 2018 International Society for Pediatric and Adolescent Diabetes guidelines have been updated in light of this research.